The global peptide therapeutics market size is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising incidences of cancer as well as metabolic diseases such as obesity, osteoporosis, and diabetes.
Peptides are types of naturally occurring biological molecules that play a crucial role in biological activities of a body. These peptides are used in the treatment of various deadly diseases such as cancer, diabetes, arthritis, and neurological disorders. The pharmaceutical research and development (R&D) departments are putting in huge efforts to develop new peptides for the treatment of chronic diseases. There are around 7000 naturally occurring peptides that are identified in the recent years, which function as ion channel ligands, neurotransmitters, hormones, and growth factors to assist several human physiologies.
As per reports of the Centers of Disease Control and Prevention (CDC), about 34.2 million cases were recorded with diabetes in the US in 2020. Furthermore, as per the same reports, the frequency of diabetes were rising rapidly over the past decades. The same study suggested in year 2020, nearly 400 babies were detected with hemophilia in the US. As per the statistics reported the National Institute of Health (NIH) in 2019, sickle cell anemia impacted about 100,000 persons in the US and around one million people around the world every year. Furthermore, according to a report published by the International Agency for Research on Cancer, about 19.3 million people globally suffered from cancer in 2020. Additionally, the same study suggested, that cancer was accounted for around 10 million deaths worldwide. According to the report published in 2020 by the World Health Organization (WHO), cardiovascular diseases caused approximately 18 million death globally every year.
The COVID-19 pandemic has showed positive impact on the peptide therapeutics market as the peptide therapeutics found its way into the treatment of COVID-19. Globally, researchers are conducting massive experiments on antibodies in a search of finding compounds that can block the infection mechanisms of SARS-CoV-2 as well as replication of SARS-CoV-2. There were extensive research activities focusing on peptides in the COVID-19 treatment and as per some surveys, as in May 2020 there were 21 peptide drugs in progress along with 15 synthetic peptides. These drug development and research activities has bolstered the market during the pandemic. The market found certain challenges in cancer research segment due to the restriction of COVID-19 across the world.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing investments in drug discovery and expansion of R&D activities mainly dedicated on the development of treatment drugs for diseases such as cancer, metabolic disorders, infectious diseases, and diabetes. This is expected to boost the market growth in the coming years.
- Existing strong pipeline of treatment products in the field of peptide therapeutics along with the advancements in the manufacturing processes are major factor driving the market growth.
- Several initiatives and policies undertaken by the governments encouraging companies for the development of new drugs with better efficacy present key drivers of the market.
- High cost along with short half-lives of the peptides drugs as well as strict regulatory policies act as major restraints, expected to hamper the market growth.
- High prevalence of chronic diseases along with extensive research activities on the development of diseases treatment are offering huge opportunities for the market expansion in the near future.
Scope of the Report
The report on the global peptide therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Peptide Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Applications (Cancers, Metabolic, Cardiovascular Disorder, Respiratory, GIT, Anti-infection, Pain, Dermatology, CNS, Renal, and Others), Types (Generic and Innovative), Types of Manufacturers (In-house and Outsourced), Routes of Administration (Parenteral Route, Oral Route, Pulmonary, Mucosal, and Others), Synthesis Technology (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis, and Hybrid Technology)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Eli Lilly and Company; Amgen Inc.; TEVA PHARMACEUTICAL INDUSTRIES LTD; Polypeptide Group; EVER Pharma GmbH; Bristol-Myers Squibb Company; Novo Nordisk A/S; Sanofi; AstraZeneca PLC; and GlaxoSmithKline PLC
Market Segment Insights
Cancer segment is expected to grow at a rapid pace
Based on applications, the global peptide therapeutics market is divided into dermatology, cancers, metabolic, anti-infection, cardiovascular disorder, respiratory, gastrointestinal tract, pain, central nervous system, renal, and others. The cancer segment is expected to grow at a rapid pace in the coming years due to the high prevalence of cancer worldwide and increase in the number of the aging population who are at risks of exposing to several chronic diseases especially cancer. The increasing preference of doctors to prescribe peptide therapeutics for the treatment of cancer is also propelling the segment. Rising awareness of patients along with the healthcare professionals in the field of peptide therapeutics is further boosting the segment growth.
The metabolic disorders segment is projected to expand at a considerable rate during the projected period owing to the rising number of these disorders due to the unhealthy food habits, sedentary lifestyle, and high alcohol consumptions. Additionally, the rising aging population is set to accelerate the segment expansion in the near future.
Generic segment is projected to expand at a considerable CAGR
On the basis of drug types, the market is bifurcated into generic and innovative. The generic segment is projected to expand at a considerable CAGR during the forecast period attributed to the rising investments by major players in the market for development of high efficacy novel drugs. Furthermore, the increasing expenditure on healthcare as well as initiative by governments across the globe and loss of patents of branded drugs are estimated to boost the market segment. The innovative segment, however, is expected to grow at a significant pace in the coming years owing to high research activities and number of products in the pipeline. Growing investment on R&D projects from key global players are proving to support the market segment growth.
In-house segment is estimated to grow at a substantial pace
Based on the manufacturing types, the global peptide therapeutics market is segmented into in-house and outsourced. The in-house segment is estimated to grow at a substantial pace during the targeted period due to rising preference for manufacturers towards in-house manufacturing techniques. The in-house system offers advantages such as large-scale production along with the wide establishment of advanced technology in the segment.
The outsourcing segment, meanwhile, is projected to show considerable growth during the forecast period due to the challenges faced by the manufacturer with high quality manufacturing standards. So, the companies outsource their active pharmaceutical ingredients (API) by the companies with advanced technology and regions where there is low-cost for labor. The increased funding in the segment by the companies as well as government are responsible for the segment to grow at a significant rate in the near future.
Parenteral segment is projected to expand at a significant rate
On the basis of routes of administration, the market is classified as oral route, parenteral route, pulmonary, mucosal, and others. The parenteral segment is projected to expand at a significant rate during the forecast period owing to high efficacy and fast rate of action along with ease of application. Several major players in the market are funding a large number of research for developing new method of drug delivery for the peptides. Meanwhile, the oral route of drug delivery is becoming popular in the market due to easy availability and patient compliance. However, certain disadvantages include degradation of the drugs through this route of administration due to the enzymes of the stomach acts as a key restraint for the market growth.
The pulmonary route, on the other hand, is expected to grow at a significant pace in the near future due to the high number of clinical trial in the segment. However, issues concerning the side-effects of inflammation caused due to the crossing of low molecular weight molecule through the alveolar epithelium along with low bioavailability are key challenges that can hinder the segment growth.
Solid phase peptide synthesis segment is anticipated to grow at a significant pace
On the basis of technology, the global peptide therapeutics market is segregated into liquid phase peptide synthesis (LPPS), solid phase peptide synthesis (SPPS), and hybrid technology. The SPPS segment is anticipated to grow at a significant pace during the targeted period owing to high demand for pure peptides, fast and more effective method in the market. The SPPS has lower synthesis time as well as high efficacy in the synthesis of longer peptides. Additionally, factors such as scalability, associated automation, and improved control over the physicochemical properties of peptides are expected to boost the market segment in the coming years. The segment is also popular in the market because of the high demand for the pure peptides.
On the other hand, the hybrid technology segment is estimated to exhibit a healthy growth rate in the coming years as this technology is compatible with LPPS and SPPS, which provide better treatment. The high investment in the segment along with the availability of inexpensive technology and sustainable are proving to boost the segment during the forecast period.
North America is anticipated to constitute a key market share
In terms of regions, the global peptide therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key market share in the coming years. The increase in awareness regarding the peptide therapeutics products, rising plea for diagnostics in cancer & other diseases, and budding biotechnology industry are the key factors contributing to the propelling the market growth in the region. Moreover, growing R&D funding by the respective governments is also proving to support the peptide therapeutics market in the region. A well-developed pharmaceutical & biopharmaceutical industry in the region is a key driving factor responsible for the regional market growth.
However, the market of Asia Pacific is anticipated to represent a considerable growth rate in the coming future attributed to low cost of raw material, high untapped opportunities, successful biotech industry, growing base of companies providing outsourcing services, and growing investments in the R&D activities in the region. Availability of inexpensive raw materials and patent termination of drugs are propelling the generic market, which is projected to offer noteworthy growth opportunities in the regional market expansion during the forecast period.
Segments Covered in the Report
The global peptide therapeutics market has been segmented on the basis of
- Cardiovascular Disorder
Types of Manufacturers
Routes of Administration
- Parenteral Route
- Oral Route
- Solid Phase Peptide Synthesis
- Liquid Phase Peptide Synthesis
- Hybrid Technology
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
Key players competing in the global peptide therapeutics market are Bristol-Myers Squibb Company; Polypeptide Group; Eli Lilly and Company; Amgen Inc.; AstraZeneca PLC; TEVA PHARMACEUTICAL INDUSTRIES LTD; EVER Pharma GmbH; Novo Nordisk A/S; Sanofi; and GlaxoSmithKline PLC.
Novo Nordisk announced to make a label extension application to the European Medicines Agency (EMA) in December 2020, for the standing marketing permission for Ozempic, which is a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to announce a new dose of 2.0 mg. In other event, Eli Lilly and Company received the US FDA approval in June 2019 for its Emgality, a calcitonin gene-related peptide (CGRP) antibody which was designed to use for the treatment of episodic cluster headache and migraine.